Coherus starts asset sale as H.C. Wainwright targets Coherus stock

Coherus Oncology (US19249H1032) began marketing its remaining legacy biosimilar assets on September 23, 2026, while H.C. Wainwright reiterated a Buy rating and set a USD 7.00 price target for Coherus stock on September 21, 2026. The combination puts the contingent value rights distribution and the company’s oncology transition at the center of the current investment case.

CVR distribution reaches holders

According to Coherus Oncology on September 23, 2026, Oppenheimer & Co. was retained to market patents, royalties, cell lines and related materials from the former biosimilars business.

The same release states that contingent value rights were scheduled for distribution on October 7, 2026, to stockholders of record on September 30, 2026. The rights provide a pro rata claim on net cash proceeds from asset sales or licensing fees, so the eventual value depends on transactions that have yet to be completed.

Revenue improves while losses persist

Markets Insider reported that Coherus generated USD 14.31 million of revenue in the second quarter of 2026, versus USD 10.25 million in the second quarter of 2025. The same report put the GAAP net loss at USD 20.63 million, compared with a USD 41.34 million loss a year earlier.

The revenue comparison is constructive, but the loss profile keeps cash conversion central to the story. Coherus describes itself as a commercial-stage oncology company built around the LOQTORZI PD-1 inhibitor and mid-stage candidates including tagmokitug and casdozokitug.

Analyst target towers over market value

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and set a USD 7.00 target on September 21, 2026, according to Markets Insider. The article also cited a USD 7.75 consensus target, but the individual rating and target remain the clearer dated reference.

Coherus had a market capitalization of USD 159.1 million as of October 6, 2026. Its 52-week range was USD 1.01 to USD 2.62 on the same date, framing the small-cap valuation against a wide trading history while the company pursues proceeds from its legacy assets.

Prior close sets the euro reference

The prior close at Lang & Schwarz was EUR 0.92 on October 5, 2026. The stock is listed on NASDAQ under CHRS, and the company operates in the Healthcare sector and Biotechnology industry.

The further course of trading is shown by the continuously updated real-time quote of Coherus Oncology stock.

More news and analyses on Coherus Oncology stock